Lack of association between levels of transplacentally acquired Plasmodium falciparum-specific antibodies and age of onset of clinical malaria in infants in a malaria endemic area of Nigeria.
A cohort of 117 newborns was followed longitudinally for 12 months to determine the age of onset of clinical malaria and the subsequent episodes of malaria, and to investigate the possible existence of a correlation between level of transplacentally acquired Plasmodium falciparum-specific antibodies and age of onset of malaria in the infant. The mean age of onset of malaria in 49 infants was 4.48 +/- 1.54 months. Mean (+/- S.D.) age of onset of clinical malaria in haemoglobin AA infants (4.38 +/- 1.14) was significantly (P < 0.05) lower compared with haemoglobin AS (5.58 +/- 2.43) infants. No correlation was obtained between the age of onset of malaria and the level of cord serum total IgG, IgM and antibodies to P. falciparum antigens. Cord blood seropositivity for antibodies to the blood stage antigen Pf155/RESA and its C-terminal repeat sequence (EENV)6 or to the (NANP)6 peptide representing repeats of the circumsporozoite protein (CSP) did not influence the age of onset of clinical malaria. However, infants with haemoglobin AS whose cord blood was seropositive for antibodies to the (EENV)6 or (NANP)6 peptide showed delayed onset (P < 0.001) of malaria compared with AA seropositive infants. Although our results indicate that transplacentally acquired antibodies to the studied antigens alone offer no significant protection against malaria during the first few months of life, antibodies in concert with other factors such as haemoglobin genotype may contribute to the protection of the newborn.
Achidi
E A
EA
Department of Chemical Pathology, University College Hospital, Ibadan, Nigeria.
Salimonu
L S
LS
Perlmann
H
H
Perlmann
P
P
Berzins
K
K
Williams
A I
AI
D000367:Age Factors; D000755:Anemia, Sickle Cell / Q000150:complications / Q000469:parasitology; D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology*; D000953:Antigens, Protozoan / Q000276:immunology; D004198:Disease Susceptibility; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007223:Infant; D007231:Infant, Newborn; D008137:Longitudinal Studies; D016778:Malaria, Falciparum / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology*; D008297:Male; D009549:Nigeria / Q000453:epidemiology; D010963:Plasmodium falciparum / Q000276:immunology*; D011247:Pregnancy
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D006454:Hemoglobins; D007074:Immunoglobulin G; D007075:Immunoglobulin M